Nivolumab for treating advanced clear cell renal cell carcinoma after systemic treatment

Subcutaneous (SC) Nivolumab is currently in clinical development for treating advanced or metastatic clear cell renal cell carcinoma (ccRCC) in adult patients who previously received systemic treatment. Metastatic cancer is when cancer cells have spread to other parts of the body and advanced cancer is when the cancer cannot be cured. ccRCC is the most common type of kidney cancer and is called as such because the cancer cells appear clear when viewed under a microscope. Most patients with renal cell carcinomas (RCC) are usually asymptomatic in the early stage, but symptoms, which include blood in the urine, pain in lower back or side, weight loss and tiredness, appear as the cancer progresses.